CLX ONC 55A9
Alternative Names: CLX-ONC-55A9Latest Information Update: 28 Apr 2024
At a glance
- Originator Cellix Bio
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Breast-cancer(Late-stage disease) in India
- 02 Mar 2020 Cellix Bio has multiple international patents, including in the US, covering its pipeline candidates (Cellix Bio website, March 2020)
- 02 Mar 2020 Preclinical trials in Breast cancer (Late-stage disease) in India (Cellix Bio pipeline, March 2020)